Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 8;10(8):e00066. doi: 10.14309/ctg.0000000000000066

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 4. — Serological detection of M30 in NAFLD patients with low liver stiffness values measured by TE. (a) A higher percentage of NAFLD patients with low TE values (<7.2 kPa or 7.9 kPa detected by FibroScan with XL or M probe) showed elevated M30 levels (>200 U/L) compared with patients with nonelevated (≤200 U/L) M30 levels. (b) Most patients with elevated M30 levels despite low TE values showed NASH. (c) Half of the NASH patients with low TE values but elevated M30 levels showed histological fibrosis. (d) Contrarily, most patients with low TE values and nonelevated M30 levels (≤200 U/L) did not reveal NASH. (e) In most patients who showed NASH, despite low TE values and nonelevated M30 levels, there was no histological evidence of fibrosis. NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; TE, transient elastography.